ADAG
Closed
Adagene Inc
1.85
-0.10 (-5.13%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.95
Day's Range: 1.74 - 2.1
Send
sign up or login to leave a comment!
When Written:
1.45
Adagene Inc is a biotechnology company that specializes in the development of innovative antibody-based immunotherapies for cancer and other diseases. The company was founded in 2011 and is headquartered in Suzhou, China, with additional offices in the United States and Australia.
Adagene's proprietary platform technology, called SAFEbody™, enables the discovery and engineering of highly specific and potent antibodies that target a wide range of disease targets. The company's pipeline includes several preclinical and clinical-stage programs for the treatment of cancer, autoimmune diseases, and infectious diseases.
Adagene has partnerships and collaborations with several leading pharmaceutical companies and research institutions, including Pfizer, Eli Lilly, and the Chinese Academy of Sciences. The company has raised over $150 million in funding to date, including a $69 million Series D financing round in 2020.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Adagene's proprietary platform technology, called SAFEbody™, enables the discovery and engineering of highly specific and potent antibodies that target a wide range of disease targets. The company's pipeline includes several preclinical and clinical-stage programs for the treatment of cancer, autoimmune diseases, and infectious diseases.
Adagene has partnerships and collaborations with several leading pharmaceutical companies and research institutions, including Pfizer, Eli Lilly, and the Chinese Academy of Sciences. The company has raised over $150 million in funding to date, including a $69 million Series D financing round in 2020.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








